# A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

> **NCT04728321** · PHASE2 · COMPLETED · sponsor: **Akeso** · enrollment: 32 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** AK104 lenvatinib
- **BIOLOGICAL:** AK104

## Key facts

- **NCT ID:** NCT04728321
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-27
- **Primary completion:** 2022-08-02
- **Final completion:** 2023-08-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04728321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04728321, "A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04728321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*